Our functional analysis shows that, in accordance with previous studies [33, 34, 64, 65], CDK13 acts an oncogene in thyroid cancer cells, identifying it as a new therapeutic target in thyroid and other cancer types. This evidence concerns the gene CDK13 and thyroid gland disorder.